Related Experiment Videos
Catestatin-A Novel Predictor of Left Ventricular Remodeling After Acute Myocardial Infarction
Dan Zhu1, Hong Xie1, Xinyu Wang1
1Department of Cardiology, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health (Peking University Third Hospital), Beijing, China.
Insights
Catestatin levels measured early after ST-elevation myocardial infarction (STEMI) can predict left ventricular remodeling. Higher catestatin levels indicate worse outcomes and increased risk when combined with NT-proBNP.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Medical Prognostics
Background:
- Catestatin is a catecholamine secretion inhibitor with known cardiovascular roles.
- Previous research linked catestatin levels to ST-elevation myocardial infarction (STEMI) prognosis.
Purpose of the Study:
- To determine if catestatin can predict left ventricular (LV) remodeling in STEMI patients.
- To assess the relationship between catestatin levels and changes in LV structure and function post-STEMI.
Main Methods:
- Plasma catestatin levels were measured in 72 STEMI patients at ER admission, Day 3 (D3), and Day 7 (D7).
- Echocardiography assessed LV parameters (LVEDD, EF, etc.) at D3 and 65 months post-STEMI.
- Changes in echocardiographic parameters from D3 to 65 months evaluated LV remodeling.
Main Results:
- Day 3 plasma catestatin levels strongly correlated with changes in LVEDD, EF, and diastolic function parameters (E, A, E', E/A, E/E').
- Elevated catestatin levels were associated with poorer ventricular function during follow-up.
- Single catestatin measurements predicted LVEDD changes; combined increases with NT-proBNP indicated the highest LV remodeling risk.
Conclusions:
- Catestatin provides significant prognostic information regarding LV remodeling after STEMI.
- Early catestatin assessment can help identify STEMI patients at risk for adverse LV remodeling.
- Combined catestatin and NT-proBNP levels offer enhanced risk stratification for LV remodeling.
Abstract:
Catestatin was discovered as a potent inhibitor of catecholamine secretion and plays important roles in the cardiovascular system. Our previous study demonstrates a close relationship between catestatin levels and prognosis of ST-elevation myocardial infarction (STEMI). Using the same population, the goal of this study is to investigate the ability of catestatin to predict left ventricular (LV) remodeling in STEMI patients. 72 patients and 30 controls were included. Catestatin was sampled after admission to the emergency room (ER), at day3 (D3), and day7 (D7) after STEMI. Echocardiography was performed at D3 and after 65 months for evaluation of LVEDD, EF, IVS, LVPW, E, A, E', E/A, and E/E'. The changes of these parameters from D3 to 65 months were used to reflect the changes of ventricular structure and function. We found that plasma catestatin levels at D3 were highly correlated with the changes of LVEDD, EF, E, A, E', E/A, as well as E/E'. Patients with higher catestatin levels developed worse ventricular function during the follow-up period. Single-point catestatin was effective to predict LVEDD change. And concurrently increasing catestatin and NT-proBNP levels predicted the highest risk of LV remodeling. This study suggests an important prognostic information of catestatin on LV remodeling.